Evidence map›Paper›PMID 36299794›Full record

ArticleNeuro-oncology advances

Germline polymorphisms in

Michael E Scheurer, Renke Zhou, Mark R Gilbert, Melissa L Bondy, Erik P Sulman, Ying Yuan, Yanhong Liu, Elizabeth Vera, Merideth M Wendland, Emad F Youssef and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Michael E ScheurerBaylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8379-6088
Renke ZhouBaylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA.
Mark R GilbertNational Institutes of Health Clinical Center, Bethesda, MD, USA.
Melissa L BondyBaylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA.
Erik P SulmanM D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA.
Ying YuanM D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-3163-480X
Yanhong LiuBaylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA.
Elizabeth VeraNational Institutes of Health Clinical Center, Bethesda, MD, USA.
Merideth M WendlandNational Cancer Institute, Bethesda, MD, USA.
Emad F YoussefArizona Oncology Services Foundation, Tucson, AZ, USA.
Volker W StieberForsyth Regional Cancer Center, Winston-Salem, NC, USA.
Ritsuko R KomakiM D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA.
John C FlickingerUPMC-Shadyside Hospital, Pittsburgh, PA, USA.
Lawrence C KenyonThomas Jefferson University Hospital, Philadelphia, PA, USA.
H Ian RobinsUniversity of Wisconsin Hospital, Madison, WI, USA.
Grant K HunterIntermountain Medical Center, Murray, UT, USA.
Ian R CrockerEmory University, Winship Cancer Institute, Atlanta, GA, USA.
Samuel T ChaoCleveland Clinic Foundation, Cleveland, OH, USA.
Stephanie L PughNRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
Terri S ArmstrongNational Institutes of Health Clinical Center, Bethesda, MD, USA.
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USNational Institutes of Health Clinical Center · USArizona Oncology · USCleveland Clinic · USEmory University · USIntermountain Medical Center · USNRG Oncology · USRegional Cancer Center · USShadyside Hospital · USTexas Oncology · USThomas Jefferson University Hospital · USUW Health University Hospital · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
National Clinical Trials Network Research at the University of WisconsinUG1CA233277 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Lisa M Barroilhet, Andrew M. Baschnagel · 2019 to 2026
$4.9M
Toxicity profiling: creating novel paradigms to personalize cancer treatmentR01NR013707 · NINR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SCHEURER, MICHAEL E. · 2013 to 2017
$2.1M
Lung Cancer Prediction Models Incorporating Exome Data from Extreme PhenotypesK07CA181480 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIU, YANHONG · 2014 to 2017
$511k
NCI NIH HHS K07 CA181480NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233277NINR NIH HHS R01 NR013707
6 · The paper itself

Abstract

Background: We sought to identify clinical and genetic predictors of temozolomide-related myelotoxicity among patients receiving therapy for glioblastoma. Methods: Patients ( Results: 23% of patients developed myelotoxicity ( Conclusions: Myelotoxicity during concurrent chemoradiation with temozolomide is an uncommon but serious event, often leading to treatment cessation. Successful prediction of toxicity may lead to more cost-effective individualized monitoring of at-risk subjects. The addition of genetic factors greatly enhanced our ability to predict toxicity among a group of similarly treated glioblastoma patients.

Indexed as

genetic associationglioblastomamyelotoxicityrisk predictiontemazolomide

Identifiers

PMID36299794
PMCPMC9587696
OpenAlexW4307495217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.